Sales and Marketing

Showing 15 posts of 11528 posts found.

NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic

September 30, 2016 Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo

The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
brian_mcnamara

GSK appoints Brian McNamara chief of consumer health division

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brian McNamara, Emma Walmsley, GlaxoSmithKline

GlaxoSmithKline PLC has named Brian McNamara the head of its consumer-health division. The new comes a week after the announcement …
abbvie-singapore

AbbVie opens its $300 million manufacturing plant in Singapore

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore

AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …
janssen_stairs_1

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
novonordisk

Novo Nordisk to cut 2% of its entire workforce

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Denmark, Novo Nordisk, diabetes, insulin, job cuts, job losses

Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …
eylea-product-box-md

NICE approves Bayer’s Eylea for NHS use

September 28, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …
abbvie_0

AbbVie and Eisai celebrate approval of new Humira indication

September 28, 2016 Research and Development, Sales and Marketing AbbVie, Eisai, Humira

AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …
gilead-sciences

Provisional NICE recommendation for Gilead’s Hepatitis C treatment

September 28, 2016 Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C

NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …

Merck elects Isabel De Paoli as CSO

September 27, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
heather_bresch_2

Price-hiked EpiPen profits 66% higher than Mylan CEO claimed

September 27, 2016 Business Services, Manufacturing and Production, Sales and Marketing Heather Bresch, Mylan, epipen

In the latest development in the Mylan EpiPen scandal, it has been discovered that CEO Heather Bresch lied to US …

CPHI Worldwide: PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules

September 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CPhI

Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) …

Pfizer decides not to break up business

September 26, 2016 Sales and Marketing Ian Read, Pfizer, United States, america

In the intervening four years, Pfizer has conducted “extensive evaluation” into the possibility, with the company reorganising into two distinct …
australian-flag-map_zps69235009

Australian pharmaceutical market to grow to be worth $25 billion by 2020

September 26, 2016 Business Services, Sales and Marketing Australia, Australian Government

The Australian market, in 2016, is currently worth over $22.85 billion and is predicted to reach $25.2 billion by 2020, …
fda2outsideweb

Sanofi and Regeneron’s atopic dermatitis drug secures FDA priority review

September 26, 2016 Research and Development, Sales and Marketing

Regeneron and Sanofi have announced that the US Food and Drug Administration has granted priority review for the pair’s atopic …
The Gateway to Local Adoption Series

Latest content


Five Facts about COPD

October 11, 2026